173 related articles for article (PubMed ID: 33720995)
1. EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model.
Rhodin MHJ; McAllister NV; Castillo J; Noton SL; Fearns R; Kim IJ; Yu J; Blaisdell TP; Panarese J; Shook BC; Or YS; Goodwin B; Lin K
PLoS Pathog; 2021 Mar; 17(3):e1009428. PubMed ID: 33720995
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.
Coates M; Brookes D; Kim YI; Allen H; Fordyce EAF; Meals EA; Colley T; Ciana CL; Parra GF; Sherbukhin V; Stockwell JA; Thomas JC; Hunt SF; Anderson-Dring L; Onions ST; Cass L; Murray PJ; Ito K; Strong P; DeVincenzo JP; Rapeport G
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652242
[TBL] [Abstract][Full Text] [Related]
3. Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.
Brookes DW; Coates M; Allen H; Daly L; Constant S; Huang S; Hows M; Davis A; Cass L; Ayrton J; Knowles I; Strong P; Rapeport G; Ito K
Br J Pharmacol; 2018 Jun; 175(12):2520-2534. PubMed ID: 29579332
[TBL] [Abstract][Full Text] [Related]
4. Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium.
Mirabelli C; Jaspers M; Boon M; Jorissen M; Koukni M; Bardiot D; Chaltin P; Marchand A; Neyts J; Jochmans D
J Antimicrob Chemother; 2018 Jul; 73(7):1823-1829. PubMed ID: 29596680
[TBL] [Abstract][Full Text] [Related]
5. Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
Blockus S; Sake SM; Wetzke M; Grethe C; Graalmann T; Pils M; Le Goffic R; Galloux M; Prochnow H; Rox K; Hüttel S; Rupcic Z; Wiegmann B; Dijkman R; Rameix-Welti MA; Eléouët JF; Duprex WP; Thiel V; Hansen G; Brönstrup M; Haid S; Pietschmann T
Antiviral Res; 2020 May; 177():104774. PubMed ID: 32197980
[TBL] [Abstract][Full Text] [Related]
6. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication
Jorquera PA; Mathew C; Pickens J; Williams C; Luczo JM; Tamir S; Ghildyal R; Tripp RA
J Virol; 2019 Feb; 93(4):. PubMed ID: 30541831
[TBL] [Abstract][Full Text] [Related]
7. [EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus].
Reina J; Iglesias C
Rev Esp Quimioter; 2023 Feb; 36(1):26-29. PubMed ID: 36401806
[TBL] [Abstract][Full Text] [Related]
8. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
[TBL] [Abstract][Full Text] [Related]
9. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
Ahmad A; Eze K; Noulin N; Horvathova V; Murray B; Baillet M; Grey L; Mori J; Adda N
N Engl J Med; 2022 Feb; 386(7):655-666. PubMed ID: 35172056
[TBL] [Abstract][Full Text] [Related]
10. Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine
Mackman RL; Hui HC; Perron M; Murakami E; Palmiotti C; Lee G; Stray K; Zhang L; Goyal B; Chun K; Byun D; Siegel D; Simonovich S; Du Pont V; Pitts J; Babusis D; Vijjapurapu A; Lu X; Kim C; Zhao X; Chan J; Ma B; Lye D; Vandersteen A; Wortman S; Barrett KT; Toteva M; Jordan R; Subramanian R; Bilello JP; Cihlar T
J Med Chem; 2021 Apr; 64(8):5001-5017. PubMed ID: 33835812
[TBL] [Abstract][Full Text] [Related]
11. Targeting Intracellular Ion Homeostasis for the Control of Respiratory Syncytial Virus.
Norris MJ; Malhi M; Duan W; Ouyang H; Granados A; Cen Y; Tseng YC; Gubbay J; Maynes J; Moraes TJ
Am J Respir Cell Mol Biol; 2018 Dec; 59(6):733-744. PubMed ID: 30095982
[TBL] [Abstract][Full Text] [Related]
12. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
[TBL] [Abstract][Full Text] [Related]
13. Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses.
Ohol YM; Wang Z; Kemble G; Duke G
PLoS One; 2015; 10(12):e0144648. PubMed ID: 26659560
[TBL] [Abstract][Full Text] [Related]
14. The Interferon Type I/III Response to Respiratory Syncytial Virus Infection in Airway Epithelial Cells Can Be Attenuated or Amplified by Antiviral Treatment.
McCutcheon KM; Jordan R; Mawhorter ME; Noton SL; Powers JG; Fearns R; Cihlar T; Perron M
J Virol; 2016 Feb; 90(4):1705-17. PubMed ID: 26608311
[TBL] [Abstract][Full Text] [Related]
15. Antiviral and Immunomodulatory Activity of Silver Nanoparticles in Experimental RSV Infection.
Morris D; Ansar M; Speshock J; Ivanciuc T; Qu Y; Casola A; Garofalo R
Viruses; 2019 Aug; 11(8):. PubMed ID: 31398832
[TBL] [Abstract][Full Text] [Related]
16. The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin.
Kim YI; Pareek R; Murphy R; Harrison L; Farrell E; Cook R; DeVincenzo J
Influenza Other Respir Viruses; 2017 Nov; 11(6):525-530. PubMed ID: 28990339
[TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of antiviral compounds on respiratory syncytial virus using a juvenile vervet monkey (Chlorocebus pygerythrus) infection model.
Houspie L; Stevens H; Ngotho M; Keyaerts E; Ispas G; Verloes R; Van Ranst M; Maes P
Methods Mol Biol; 2013; 1030():373-82. PubMed ID: 23821283
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs.
Salinas FM; Nebreda AD; Vázquez L; Gentilini MV; Marini V; Benedetti M; Nabaes Jodar MS; Viegas M; Shayo C; Bueno CA
Antiviral Res; 2020 Jul; 179():104817. PubMed ID: 32387475
[TBL] [Abstract][Full Text] [Related]
19. RFI-641, a potent respiratory syncytial virus inhibitor.
Huntley CC; Weiss WJ; Gazumyan A; Buklan A; Feld B; Hu W; Jones TR; Murphy T; Nikitenko AA; O'Hara B; Prince G; Quartuccio S; Raifeld YE; Wyde P; O'Connell JF
Antimicrob Agents Chemother; 2002 Mar; 46(3):841-7. PubMed ID: 11850270
[TBL] [Abstract][Full Text] [Related]
20. Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.
Villenave R; Broadbent L; Douglas I; Lyons JD; Coyle PV; Teng MN; Tripp RA; Heaney LG; Shields MD; Power UF
J Virol; 2015 Dec; 89(24):12309-18. PubMed ID: 26423940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
